Avalo Therapeutics
Biopharmaceutical company
Based in MD
🤖
AI Overview
With $260K in lobbying spend across 14 quarterly filings, Avalo Therapeutics is an active lobbying client. Their lobbying covers 4 issue areas. Active from 2021 to 2023.
$260K
Total Spend
3
Years Active
1
Firms Hired
1
Lobbyists Deployed
4
Issues Lobbied
Spending Trend
View as table
| Year | Lobbying Spend |
|---|---|
| 2021 | $80K |
| 2022 | $150K |
| 2023 | $30K |
Issues Lobbied
Lobbying Firms
Lobbyists
What They Lobby About
These are actual descriptions from their quarterly lobbying disclosure filings, summarizing what they lobbied Congress and federal agencies about.Issue areas: Budget/Appropriations, Health Issues, Pharmacy, MED
- •Appropriations and funding for client projects, products, and services; Drug Pricing, Rare Disease Cures, cell and gene therapy.
- •Medical Countermeasures Development of Therapeutics for COVID-19 and Rare Disease
Related Analysis
Related Investigations
The 22,000% ROI
When lobbying spending yields outsized returns.
Big Pharma's $452M Lobbying Machine
How pharmaceutical companies spend hundreds of millions to influence health policy.
Healthcare's $3 Billion Bet
The healthcare industry's massive lobbying investment.
Federal Lobbying Statistics 2025
The definitive stats — $37.7B total, industry breakdowns, and trends.
What Is Lobbying? A Complete Guide
How lobbying works, who does it, and why it matters.
Similar Clients
Sickle Cell Disease Association of America
$200K total spend
Stonington Global (Obo, Maimonides Medical Center)
$75K total spend
Stonington Global (Obo, Sorrento Therapeutics)
$50K total spend
The United States Pharmacopeial Convention
$2.6M total spend
The National Alliance for Eye and Vision Research
$2.0M total spend
Explore More
Data Sources: Senate LDA Filings
Last updated: February 2026
This site is an independent journalism project. Analysis and editorial content are not affiliated with or endorsed by any government agency.